2001
DOI: 10.1056/nejm200104053441401
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed. Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

34
2,811
5
74

Year Published

2004
2004
2014
2014

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 4,555 publications
(2,924 citation statements)
references
References 19 publications
34
2,811
5
74
Order By: Relevance
“…Defining BcrAbl as the molecule driving the disease led to development of the tyrosine kinase inhibitor imatinib as the first targeted therapy for leukemia (Druker et al, 2001). Nevertheless, identification of new pathways and molecules activated by Bcr-Abl offers new insights into the pathophysiology of CML and may also be useful to further develop molecular therapy.…”
Section: Introductionmentioning
confidence: 99%
“…Defining BcrAbl as the molecule driving the disease led to development of the tyrosine kinase inhibitor imatinib as the first targeted therapy for leukemia (Druker et al, 2001). Nevertheless, identification of new pathways and molecules activated by Bcr-Abl offers new insights into the pathophysiology of CML and may also be useful to further develop molecular therapy.…”
Section: Introductionmentioning
confidence: 99%
“…The marked breed association of specific tumors such as gliomas with brachycephalic breeds7, 9, 12, 18 may provide an opportunity to decrease incidence by selective breeding once provisionally defined genetic associations22, 23 are further characterized. Most of the recent major advances in human oncology have been made by elimination of environmental factors such as smoking, improved screening, and use of targeted therapies in cancers such as chronic myelogenous leukemia and breast cancer 24, 25. For neurooncology specifically, only 2 new drugs have been approved by the FDA for treatment of high‐grade gliomas in humans in the last 30 years, the chemotherapeutic temozolamide,1 which increases overall median survival in humans with grade IV astrocytomas/glioblastoma multiforme by approximately 12 weeks,26 and bevacizumab,2 which was given fast track approval, but has recently been shown to have limited if any survival benefit in a large prospective phase III clinical trial 27.…”
mentioning
confidence: 99%
“…Targeting constitutively activated tyrosine kinases has produced highly effect anticancer therapeutics, notably imatinib mesylate/ Gleevec/STI-571 (29) and trastuzumab/Herceptin. (30) The development of molecular therapies targeted specifically at sarcomas is confounded by the complex karyotypes and lack of consistent genetic changes among the majority of subtypes, notably OS.…”
Section: Discussionmentioning
confidence: 99%